Rhenman & Partners Asset Management AB
In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 13, 2025), Rhenman & Partners Asset Management AB reported 92 stock positions worth $972.9 million. Its top holding was Boston Scientific (BSX) at 4.1% of the portfolio, followed by Eli Lilly (LLY, 3.6%) and Procept Biorobotics (PRCT, 3.5%). Compared with Q3 2024, it opened 2 new positions, sold out of 5, added to 29 and reduced 54. The biggest buy was a new position in Zimmer Biomet (ZBH) and the biggest sale HCA Healthcare (HCA, shares −55%).
- Most Recent 13F
- Q2 2026
- Location
- Stockholm, V7
- CIK
- 0001599882
- Portfolio Value
- $972.9M (Q4 2024)
- SEC Filing
- 0001213900-25-013150 ↗ filed Feb 13, 2025
Holdings Value
Holdings 92 stocks · $972.9M
| BSX Boston Scientific Corp. | 4.08% | 444,000 | $39.7M | Reduce -24.8% |
| LLY Eli Lilly & Co. | 3.61% | 45,450 | $35.1M | Reduce -4.3% |
| PRCT Procept Biorobotics Corp. | 3.48% | 420,345 | $33.8M | Reduce -5.5% |
| ISRG Intuitive Surgical Inc. | 3.43% | 64,000 | $33.4M | Add +1.6% |
| REGN Regeneron Pharmaceuticals | 3.18% | 43,457 | $31.0M | Add +11.4% |
| UNH Unitedhealth Group Inc. | 3.15% | 60,530 | $30.6M | Reduce -16.7% |
| INSP Inspire Medical Systems Inc. | 2.86% | 150,041 | $27.8M | Add +23.0% |
| MRK Merck & Co. Inc. | 2.84% | 277,500 | $27.6M | Add +15.2% |
| EXAS Exact Sciences Corp. | 2.72% | 471,000 | $26.5M | Add +1.3% |
| THC Tenet Healthcare Corp. | 2.56% | 197,700 | $25.0M | Reduce -10.7% |
| GILD Gilead Sciences Inc. | 2.43% | 255,500 | $23.6M | Reduce -30.3% |
| ABBV Abbvie Inc. | 2.27% | 124,150 | $22.1M | Reduce -29.9% |
| CI The Cigna Group | 2.22% | 78,385 | $21.6M | Add +88.0% |
| MDT Medtronic PLC | 2.21% | 269,500 | $21.5M | Reduce -26.8% |
| VRTX Vertex Pharmaceuticals Inc. | 2.07% | 50,000 | $20.1M | Add +4.7% |
| ALHC Alignment Healthcare Inc. | 2.04% | 1,761,192 | $19.8M | Reduce -10.9% |
| NTRA Natera Inc. | 2.01% | 123,410 | $19.5M | Reduce -46.6% |
| MCK McKesson Corp. | 2.00% | 34,117 | $19.4M | Add +13.3% |
| BIIB Biogen Inc. | 1.94% | 123,700 | $18.9M | Add +84.3% |
| OSCR Oscar Health Inc. Class A | 1.88% | 1,362,421 | $18.3M | Reduce -0.6% |
| JAZZ Jazz Pharmaceuticals PLC | 1.84% | 145,500 | $17.9M | Add +56.5% |
| BMRN Biomarin Pharmaceutical Inc. | 1.69% | 250,623 | $16.5M | Reduce -31.2% |
| RPRX Royalty Pharma PLC Class A | 1.56% | 595,000 | $15.2M | Reduce -3.0% |
| PODD Insulet Corp. | 1.53% | 57,000 | $14.9M | Add +42.5% |
| ITCI Intra-Cellular Therapies Inc. | 1.51% | 176,000 | $14.7M | Reduce -14.4% |
| DHR Danaher Corp. | 1.51% | 63,952 | $14.7M | Reduce -23.2% |
| ABT Abbott Laboratories | 1.49% | 128,000 | $14.5M | Reduce -5.2% |
| HUM Humana Inc. | 1.44% | 55,230 | $14.0M | Add +78.2% |
| NBIX Neurocrine Biosciences Inc. | 1.41% | 100,317 | $13.7M | Add +39.8% |
| ZBH Zimmer Biomet Holdings Inc. | 1.35% | 124,000 | $13.1M | New |
| COR Cencora Inc. | 1.24% | 53,750 | $12.1M | Add +19.1% |
| CVS CVS Health Corp. | 1.23% | 267,500 | $12.0M | Add +45.4% |
| CNC Centene Corp. | 1.22% | 195,482 | $11.8M | Add +67.1% |
| BDX Becton Dickinson and Co. | 1.12% | 47,900 | $10.9M | Reduce -57.4% |
| DVAX Dynavax Technologies Corp. | 1.10% | 839,131 | $10.7M | Reduce -29.5% |
| COO The Cooper Cos Inc. | 1.09% | 115,000 | $10.6M | Reduce -49.6% |
| AXSM Axsome Therapeutics Inc. | 1.07% | 122,600 | $10.4M | No change |
| HCA HCA Healthcare Inc. | 1.06% | 34,379 | $10.3M | Reduce -54.9% |
| MOH Molina Healthcare Inc. | 1.02% | 34,200 | $10.0M | Add +15.5% |
| IOVA Iovance Biotherapeutics Inc. | 0.94% | 1,235,448 | $9.1M | Add +17.4% |
| JANX Janux Therapeutics Inc. | 0.94% | 170,000 | $9.1M | Add +59.1% |
| ALGN Align Technology Inc. | 0.90% | 41,900 | $8.7M | Reduce -23.8% |
| ELV Elevance Health Inc. | 0.88% | 23,150 | $8.5M | Reduce -54.2% |
| TMO Thermo Fisher Scientific Inc. | 0.84% | 15,640 | $8.1M | Reduce -37.7% |
| SYK Stryker Corp. | 0.83% | 22,500 | $8.1M | Reduce -2.2% |
| TGTX TG Therapeutics Inc. | 0.81% | 262,500 | $7.9M | Add +53.1% |
| IONS Ionis Pharmaceuticals Inc. | 0.76% | 212,500 | $7.4M | Add +9.0% |
| CYTK Cytokinetics Inc. | 0.72% | 149,250 | $7.0M | Reduce -17.3% |
| APLS Apellis Pharmaceuticals Inc. | 0.64% | 195,591 | $6.2M | Reduce -46.8% |
| BNTX Biontech SE-ADR | 0.62% | 52,750 | $6.0M | Add +3.4% |
| IQV Iqvia Holdings Inc. | 0.59% | 29,000 | $5.7M | Reduce -39.6% |
| NUVL Nuvalent Inc. Class A | 0.58% | 72,500 | $5.7M | Reduce -19.4% |
| UHS Universal Health Services-B | 0.57% | 30,900 | $5.5M | Add +286.3% |
| GKOS Glaukos Corp. | 0.56% | 36,531 | $5.5M | Reduce -67.1% |
| NRIX Nurix Therapeutics Inc. | 0.56% | 290,000 | $5.5M | Reduce -3.3% |
| EHC Encompass Health Corp. | 0.53% | 56,000 | $5.2M | Reduce -8.2% |
| XNCR Xencor Inc. | 0.46% | 195,750 | $4.5M | Reduce -3.9% |
| NVO Novo-Nordisk A/S-Spons ADR | 0.44% | 50,000 | $4.3M | Reduce -50.0% |
| INSM Insmed Inc. | 0.44% | 61,500 | $4.2M | Reduce -52.5% |
| ESPR Esperion Therapeutics Inc. | 0.43% | 1,915,000 | $4.2M | Reduce -3.0% |
| ALNY Alnylam Pharmaceuticals Inc. | 0.41% | 17,000 | $4.0M | Reduce -66.2% |
| KRYS Krystal Biotech Inc. | 0.38% | 23,750 | $3.7M | Add +39.7% |
| VKTX Viking Therapeutics Inc. | 0.37% | 90,000 | $3.6M | Reduce -12.2% |
| IMVT Immunovant Inc. | 0.37% | 145,000 | $3.6M | Reduce -40.3% |
| GERN Geron Corp. | 0.36% | 1,000,000 | $3.5M | No change |
| ACLX Arcellx Inc. | 0.34% | 43,500 | $3.3M | Add +35.9% |
| MRUS Merus NV | 0.32% | 74,500 | $3.1M | Reduce -6.3% |
| SNDX Syndax Pharmaceuticals Inc. | 0.32% | 232,000 | $3.1M | Reduce -10.6% |
| MIRM Mirum Pharmaceuticals Inc. | 0.31% | 73,755 | $3.0M | Reduce -29.8% |
| ARVN Arvinas Inc. | 0.31% | 155,500 | $3.0M | Add +19.2% |
| ANNX Annexon Inc. | 0.29% | 542,500 | $2.8M | Reduce -3.1% |
| CRL Charles River Laboratories | 0.28% | 14,850 | $2.7M | Reduce -60.4% |
| KURA Kura Oncology Inc. | 0.28% | 314,526 | $2.7M | Add +88.9% |
| ASTH Astrana Health Inc. | 0.26% | 80,000 | $2.5M | New |
| DNTH Dianthus Therapeutics Inc. | 0.26% | 114,000 | $2.5M | Reduce -24.0% |
| TMDX Transmedics Group Inc. | 0.24% | 38,000 | $2.4M | Reduce -16.1% |
| PRVA Privia Health Group Inc. | 0.24% | 121,189 | $2.4M | Add +27.3% |
| MEDP Medpace Holdings Inc. | 0.23% | 6,800 | $2.3M | Reduce -9.3% |
| ALKS Alkermes PLC | 0.23% | 77,999 | $2.2M | Reduce -41.4% |
| BRKR Bruker Corp. | 0.22% | 36,315 | $2.1M | Reduce -18.1% |
| IDYA Ideaya Biosciences Inc. | 0.22% | 82,000 | $2.1M | Reduce -35.7% |
| RLAY Relay Therapeutics Inc. | 0.19% | 460,000 | $1.9M | No change |
| IMCR Immunocore Holdings PLC-ADR | 0.18% | 58,278 | $1.7M | No change |
| PLRX Pliant Therapeutics Inc. | 0.16% | 116,250 | $1.5M | Reduce -3.3% |
| XENE Xenon Pharmaceuticals Inc. | 0.14% | 35,000 | $1.4M | No change |
| AVTR Avantor Inc. | 0.13% | 61,826 | $1.3M | Add +40.5% |
| RGEN Repligen Corp. | 0.13% | 9,000 | $1.3M | Reduce -10.0% |
| INMB Inmune Bio Inc. | 0.09% | 178,284 | $833K | No change |
| AMGN Amgen Inc. | 0.08% | 3,000 | $782K | No change |
| IGMS Igm Biosciences Inc. | 0.08% | 126,064 | $770K | Reduce -32.0% |
| ACHC Acadia Healthcare Co. Inc. | 0.06% | 13,750 | $545K | Reduce -87.0% |
| TECH Bio-Techne Corp. | 0.02% | 3,000 | $216K | Reduce -85.0% |
Portfolio Sells Q3 2024 → Q4 2024
| HCA HCA Healthcare Inc. | Reduce -54.9% | 1.06% | −1.45 |
| ELV Elevance Health Inc. | Reduce -54.2% | 0.88% | −1.25 |
| BDX Becton Dickinson and Co. | Reduce -57.4% | 1.12% | −1.08 |
| COO The Cooper Cos Inc. | Reduce -49.6% | 1.09% | −0.96 |
| ALNY Alnylam Pharmaceuticals Inc. | Reduce -66.2% | 0.41% | −0.71 |
| GKOS Glaukos Corp. | Reduce -67.1% | 0.56% | −0.61 |
| EVH Evolent Health Inc. Class A | Sold out | 0.00% | −0.61 |
| ABBV Abbvie Inc. | Reduce -29.9% | 2.27% | −0.57 |
| BBIO Bridgebio Pharma Inc. | Sold out | 0.00% | −0.55 |
| NVO Novo-Nordisk A/S-Spons ADR | Reduce -50.0% | 0.44% | −0.52 |
| ACHC Acadia Healthcare Co. Inc. | Reduce -87.0% | 0.06% | −0.49 |
| OSCR Oscar Health Inc. Class A | Reduce -0.6% | 1.88% | −0.48 |
| MDT Medtronic PLC | Reduce -26.8% | 2.21% | −0.48 |
| DXCM Dexcom Inc. | Sold out | 0.00% | −0.47 |
| TMO Thermo Fisher Scientific Inc. | Reduce -37.7% | 0.84% | −0.42 |
| THC Tenet Healthcare Corp. | Reduce -10.7% | 2.56% | −0.42 |
| EPIX Essa Pharma Inc. | Sold out | 0.00% | −0.40 |
| BMRN Biomarin Pharmaceutical Inc. | Reduce -31.2% | 1.69% | −0.39 |
| NTRA Natera Inc. | Reduce -46.6% | 2.01% | −0.37 |
| DHR Danaher Corp. | Reduce -23.2% | 1.51% | −0.37 |
| IQV Iqvia Holdings Inc. | Reduce -39.6% | 0.59% | −0.34 |
| TMDX Transmedics Group Inc. | Reduce -16.1% | 0.24% | −0.33 |
| INSM Insmed Inc. | Reduce -52.5% | 0.44% | −0.33 |
| CRL Charles River Laboratories | Reduce -60.4% | 0.28% | −0.32 |
| UNH Unitedhealth Group Inc. | Reduce -16.7% | 3.15% | −0.30 |
| MDGL Madrigal Pharmaceuticals Inc. | Sold out | 0.00% | −0.26 |
| ALGN Align Technology Inc. | Reduce -23.8% | 0.90% | −0.24 |
| APLS Apellis Pharmaceuticals Inc. | Reduce -46.8% | 0.64% | −0.22 |
| IMVT Immunovant Inc. | Reduce -40.3% | 0.37% | −0.19 |
| IGMS Igm Biosciences Inc. | Reduce -32.0% | 0.08% | −0.17 |
| NUVL Nuvalent Inc. Class A | Reduce -19.4% | 0.58% | −0.16 |
| VKTX Viking Therapeutics Inc. | Reduce -12.2% | 0.37% | −0.15 |
| IDYA Ideaya Biosciences Inc. | Reduce -35.7% | 0.22% | −0.11 |
| TECH Bio-Techne Corp. | Reduce -85.0% | 0.02% | −0.11 |
| SNDX Syndax Pharmaceuticals Inc. | Reduce -10.6% | 0.32% | −0.09 |
| DNTH Dianthus Therapeutics Inc. | Reduce -24.0% | 0.26% | −0.08 |
| ALKS Alkermes PLC | Reduce -41.4% | 0.23% | −0.07 |
| GILD Gilead Sciences Inc. | Reduce -30.3% | 2.43% | −0.07 |
| CYTK Cytokinetics Inc. | Reduce -17.3% | 0.72% | −0.05 |
| BRKR Bruker Corp. | Reduce -18.1% | 0.22% | −0.03 |
| MIRM Mirum Pharmaceuticals Inc. | Reduce -29.8% | 0.31% | −0.02 |
| MRUS Merus NV | Reduce -6.3% | 0.32% | −0.00 |
| RGEN Repligen Corp. | Reduce -10.0% | 0.13% | +0.01 |
| NRIX Nurix Therapeutics Inc. | Reduce -3.3% | 0.56% | +0.01 |
| ANNX Annexon Inc. | Reduce -3.1% | 0.29% | +0.02 |
| DVAX Dynavax Technologies Corp. | Reduce -29.5% | 1.10% | +0.03 |
| MEDP Medpace Holdings Inc. | Reduce -9.3% | 0.23% | +0.03 |
| PLRX Pliant Therapeutics Inc. | Reduce -3.3% | 0.16% | +0.05 |
| EHC Encompass Health Corp. | Reduce -8.2% | 0.53% | +0.05 |
| BSX Boston Scientific Corp. | Reduce -24.8% | 4.08% | +0.06 |
Portfolio Buys Q3 2024 → Q4 2024
| ZBH Zimmer Biomet Holdings Inc. | New | 1.35% | +1.35 |
| CI The Cigna Group | Add +88.0% | 2.22% | +1.05 |
| JAZZ Jazz Pharmaceuticals PLC | Add +56.5% | 1.84% | +1.00 |
| ISRG Intuitive Surgical Inc. | Add +1.6% | 3.43% | +0.92 |
| BIIB Biogen Inc. | Add +84.3% | 1.94% | +0.89 |
| MCK McKesson Corp. | Add +13.3% | 2.00% | +0.79 |
| PODD Insulet Corp. | Add +42.5% | 1.53% | +0.77 |
| INSP Inspire Medical Systems Inc. | Add +23.0% | 2.86% | +0.77 |
| NBIX Neurocrine Biosciences Inc. | Add +39.8% | 1.41% | +0.74 |
| HUM Humana Inc. | Add +78.2% | 1.44% | +0.64 |
| MRK Merck & Co. Inc. | Add +15.2% | 2.84% | +0.62 |
| JANX Janux Therapeutics Inc. | Add +59.1% | 0.94% | +0.54 |
| CNC Centene Corp. | Add +67.1% | 1.22% | +0.50 |
| TGTX TG Therapeutics Inc. | Add +53.1% | 0.81% | +0.49 |
| UHS Universal Health Services-B | Add +286.3% | 0.57% | +0.42 |
| COR Cencora Inc. | Add +19.1% | 1.24% | +0.42 |
| CVS CVS Health Corp. | Add +45.4% | 1.23% | +0.30 |
| VRTX Vertex Pharmaceuticals Inc. | Add +4.7% | 2.07% | +0.27 |
| ASTH Astrana Health Inc. | New | 0.26% | +0.26 |
| MOH Molina Healthcare Inc. | Add +15.5% | 1.02% | +0.20 |
| EXAS Exact Sciences Corp. | Add +1.3% | 2.72% | +0.15 |
| IOVA Iovance Biotherapeutics Inc. | Add +17.4% | 0.94% | +0.14 |
| KRYS Krystal Biotech Inc. | Add +39.7% | 0.38% | +0.13 |
| IONS Ionis Pharmaceuticals Inc. | Add +9.0% | 0.76% | +0.13 |
| BNTX Biontech SE-ADR | Add +3.4% | 0.62% | +0.13 |
| ACLX Arcellx Inc. | Add +35.9% | 0.34% | +0.13 |
| PRVA Privia Health Group Inc. | Add +27.3% | 0.24% | +0.10 |
| ARVN Arvinas Inc. | Add +19.2% | 0.31% | +0.05 |
| AVTR Avantor Inc. | Add +40.5% | 0.13% | +0.04 |
| KURA Kura Oncology Inc. | Add +88.9% | 0.28% | +0.02 |
| REGN Regeneron Pharmaceuticals | Add +11.4% | 3.18% | −0.15 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 99 | $1.1B | UNH, CVS, AZN, MRK, LLY |
| Q1 2026 | 86 | $810.5M | BSX, REGN, LLY, INSM, CVS |
| Q4 2025 | 94 | $1.1B | REGN, LLY, BSX, MDT, ISRG |
| Q3 2025 | 92 | $903.7M | BSX, LLY, ABBV, DHR, ALHC |
| Q2 2025 | 90 | $791.0M | LLY, BSX, VRTX, GKOS, ISRG |
| Q1 2025 | 94 | $870.0M | UNH, LLY, VRTX, MCK, BSX |
| Q4 2024 | 92 | $972.9M | BSX, LLY, PRCT, ISRG, REGN |
| Q3 2024 | 95 | $1.2B | BSX, UNH, LLY, REGN, THC |
| Q2 2024 | 93 | $1.0B | UNH, ELV, BSX, LLY, REGN |
| Q1 2024 | 84 | $1.1B | CI, LLY, THC, BSX, ELV |